AbbVie Inc (ABBV)vsConcentra Group Holdings Parent, Inc. (CON)
ABBV
AbbVie Inc
$230.01
+0.06%
HEALTHCARE · Cap: $391.50B
CON
Concentra Group Holdings Parent, Inc.
$25.32
+1.61%
HEALTHCARE · Cap: $3.60B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2714% more annual revenue ($62.82B vs $2.23B). CON leads profitability with a 8.0% profit margin vs 5.8%. CON trades at a lower P/E of 20.2x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
CON
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$230.01
$83.79 premium
Intrinsic value data unavailable for CON.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Every $100 of equity generates 42 in profit
Earnings expanding 29.4% YoY
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
8.0% margin — thin
Weak financial health signals
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : CON
The strongest argument for CON centers on Return on Equity, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : CON
The primary concerns for CON are Profit Margin, Piotroski F-Score, Altman Z-Score. Debt-to-equity of 5.00 is elevated, increasing financial risk.
Key Dynamics to Monitor
CON is growing revenue faster at 13.7% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 59/100) and 12.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Concentra Group Holdings Parent, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Concentra Group Holdings Parent, Inc. (Ticker: CON) is a dynamic diversified holding company focused on acquiring and managing businesses in high-growth sectors, including healthcare, technology, and infrastructure. With a strong commitment to operational excellence and innovation, Concentra employs its experienced leadership team to drive portfolio optimization through strategic investments and hands-on management. This proactive approach enables the company to effectively seize emerging trends and opportunities, positioning it as a compelling investment for institutional investors seeking diversification into high-potential markets.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?